<p>Ionis Pharmaceuticals Inc. and Otsuka Pharmaceutical Co., Ltd. announced that the European Commission has approved DAWNZERA™ (donidalorsen) for the routine prevention of recurrent attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older in the European Union. The approval is based on positive results from the Phase 3 OASIS-HAE and OASISplus studies, where DAWNZERA demonstrated a significant reduction in HAE attack rates. Otsuka holds exclusive rights to commercialize DAWNZERA in Europe and Asia Pacific. With this approval, Ionis is eligible for a milestone payment of $15 million and tiered royalties up to 30% on net product sales. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ionis Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260119050072) on January 21, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>

OTSKY

IONS

4578

EU Approves Ionis Pharmaceuticals' DAWNZERA for Hereditary Angioedema Prevention